Introduction
Systemic analgesia in labor was introduced as an alternative to inhalational analgesia. Use of these agents, mostly opioids, was common in the early stages of labor or where neuraxial analgesia was not available or contraindicated. Systemic opioids have since become less popular because they produce incomplete analgesia and frequent neonatal and maternal side effects, depending on type and dose of drug used.
Common opioids employed for systemic labor analgesia are meperidine (pethidine), morphine, fentanyl, nalbuphine, butorphanol and the newer piperidine derivatives (alfentanil, sufentanil and remifentanil). The clinical effects of the opioids usually parallel their plasma concentration but with a 'temporal shift' effect [1] (i.e. there is a delay between achievement of therapeutic plasma concentrations and clinical effect), accounted for by introduction of the 'hypnotic effect compartment'. The cogeners of fentanyl, methadone and morphine, have been characterized according to their pharmacokinetic/ pharmacodynamic profiles. Remifentanil and alfentanil have the fastest equilibrium half-lives between plasma and effect site, of 1 min, followed by fentanyl and sufentanil (equilibrium half-life 6 min), and morphine (equilibrium half-life 2-3 h).
The current challenge in the field of systemic analgesia research is to identify the ideal opioid, with optimal pharmacokinetic properties; rapid onset and offset of action, irrespective of course of administration; and flexibility in terms of the dose that may be administered as labor progresses.
Meperidine
Meperidine (pethidine) is the opioid most widely used for labor analgesia [2] because of familiarity and low cost, although its analgesic efficacy has been challenged. For instance, Soontrapa et al.
[3] identified pain relief in only 25% of patients treated intravenously with this opioid. Moreover, Olofsson et al. [4] found no substantial analgesic effect, except for sedation. Some authors still report effective analgesia with intramuscular meperidine, however. The efficacy of intramuscular meperidine (100 mg) was evaluated in a double-blind, randomized study conducted in 50 Chinese parturients [5] . The control group received normal saline. The study was terminated after an interim analysis revealed significant pain relief in the meperidine group. Neonatal side effects of meperidine have been well documented [2, [6] [7] [8] and occur as a result of the drug's prolonged half-life (2.5-3 h in the mother and 18-23 h in the neonate [9] ) and accumulation of active metabolites (e.g. normeperidine, which has a half-life of 60 h in the neonate). The latter may account for the subtle neonatal depression that may persist for 3-5 days after birth [8] , even with use of low doses of meperidine [10] .
Two recent studies compared meperidine delivered by patient-controlled intravenous analgesia (PCIA) [7] or intramuscularly [11] with PCIA remifentanil. Volikas [7] found that PCIA with a 10 mg meperidine bolus and a lockout period of 5 min resulted in low Apgar scores, which led to termination of the study after 17 patients had been enrolled. In the second study, intramuscular meperidine provided lesser pain relief than PCIA remifentanil, but the minimum maternal saturation and Apgar scores did not differ significantly between the two groups [11] .
The fetal acid-base balance was studied in a meta-analysis comparing systemic opioid analgesia with epidural analgesia in five countries [12] . The meta-analysis included eight randomized studies, with a total of 1098 infants in the epidural group and 1004 infants in the group receiving systemic analgesia. The meta-analysis found better acid-base figures (pH and bases excess) after labor in the epidural group.
Recently, Nelson et al. [13] compared the analgesic effect of intravenous butorphanol 1 mg, meperidine 50 mg, and a combination of these agents (at 0.5 mg and 20 mg, respectively). Overall, 29% of parturients exhibited meaningful pain relief, with no difference between the groups. Keskin et al. [14] compared the analgesic efficacy of meperidine (100 mg intramuscular) with that of tramadol (100 mg intramuscular) -a new analgesic with m agonistic and tricyclic antidepressant effects. Pain relief was greater in the meperidine group. The incidences of nausea and fatigue were higher in the tramadol group. None of the neonates developed respiratory depression or low Apgar scores. Claahsen-van der Grinten et al. [15] found that tramadol is readily able to traverse the placenta and so reach the neonate, but the neonate's liver is required to metabolize tramadol to its active metabolite. Renal elimination of the active tramadol metabolite M 1 was found to be delayed in neonates.
Fentanyl and its congeners
Fentanyl is a highly lipid soluble and protein-bound synthetic opioid with analgesic potency that is 800 times higher than that of meperidine. The time to peak effect of fentanyl is 3-4 min, but after repeated doses its contextsensitive decrement time (i.e. the time to a 50% reduction in blood concentration after cessation of a steady infusion) increases [16] . Several studies have found that intravenous fentanyl is superior to meperidine in managing labor pain [17, 18] , although fentanyl may have a dose-dependent adverse impact on infant feeding following birth [19] . Other studies [20, 21] of use of PCIA to manage labor pain for up to 5 h found that fentanyl was well tolerated, and there were no neonatal neurobehavioral side effects. Naloxone was needed in 37% of the neonates, however. Oxygen saturation was recorded for up to 12 h in these neonates.
Rayburn et al. [22] compared 10 mg continuous infusion plus 10 mg boluses (12 min lockout interval) with administration by a nurse of a loading dose of fentanyl 50 mg plus a 50-100 mg dose every hour as needed. The two modes of administration resulted in similar degrees of pain relief in labor, sedation and neonatal outcome.
A potential advantage of fentanyl stems from the other various ways in which the drug can be administered: oral, transdermal (patch), and subcutaneous.
Alfentanil
Alfentanil is less lipophilic and more protein bound than are other opioids. Its low volume of distribution results in a rapid onset of action (1 min) and short duration. Its contextsensitive decrement time is shorter than that for fentanyl when it is administered for a longer period of time. Its neonatal neurobehavioral depressant effect is greater than that for meperidine [23] , and its analgesic effect during PCIA administration is less than that yielded by fentanyl [20] . Alfentanil has not gained popularity as a systemic opioid for achieving labor analgesia.
Sufentanil
Sufantanil has increased lipophilicity and potency, and its time to peak effect is slow (4-6 min), but its contextsensitive decrement time is shorter even after prolonged administration [16] . It is widely used for intrathecal and epidural analgesia during labor, but it has limited utility as a systemic analgesic because of its lower potency. When it is given epidurally or intravenously, sufantanil 10 mg did not provide satisfactory analgesia, but it was more effective when given intrathecally [24] . Potential adverse effects of sufantanil include possible placental deposition of the drug and neonatal respiratory depression [24] .
Remifentanil
Remifentanil is a novel m-receptor agonist that has been used in surgical and obstetric anesthesia and analgesia for nearly a decade. It has been suggested that is may be the ideal opioid for PCIA in labor because of its pharmacokinetic and pharmacodynamic properties. As a pure m-receptor agonist drug, it retains all of the pharmacodynamic properties of its class. The pharmacokinetics of remifentanil have been extensively studied because of its unique features, including rapid onset of effect (approximately 1 min), rapid degradation by plasma and tissue esterase to inactive metabolites, and a constant context-sensitive half-life of approximately 3 min with a T 1/2 Keo (the time required for the biophase concentration to reach 50% of the plasma concentration) of 1.3 min [25] [26] [27] . Therefore, it does not accumulate even after prolonged administration. Similar to other m-opioid agonists, remifentanil has no genotoxic effects [28] . After a similar dose delivered by intravenous infusion, the plasma concentration in the pregnant women is half that in the nonpregnant woman [29] . The umbilical artery : umbilical vein ratio for remifentanil concentration is 0.29, suggesting that remifentanil crosses the placenta readily, but it is eliminated rapidly in the neonate as a result of rapid metabolism and large volume of redistribution [29] . These characteristics were confirmed in pediatric surgery patients [30] . The rapid onset of effect and elimination of remifentanil facilitate its effective and safe use during labor, because the need for analgesia increases as labor progresses, and the time from analgesic administration to clinical effect is often difficult to predict [31, 32] .
The beneficial analgesic effects of remifentanil during labor and lack of significant maternal and neonatal side effects were first identified when the drug was used as an adjunct to epidural or general anesthesia for cesarean delivery and in parturients with pre-eclampsia and cardiomyopathy [29, [33] [34] [35] . The efficacy of remifentanil as systemic analgesic for labor pain was subsequently reported in a few case series, with inconsistent findings in relation to maternal and neonatal adverse effects with various doses and modes of administration [36] [37] [38] . At doses that were too small, the technique was found to lack efficacy, whereas larger doses were associated with a high incidence of side effects. A variety of doses and delivery systems were considered in order to identify an efficient and safe approach to administration of the drug. Volikas et al. [7] compared PCIA remifentanil using a bolus dose of 0.5 mg/kg and 5 min lockout interval with PCIA meperidine using a 10 mg bolus and 10 min lockout interval. Pain scores were reduced significantly during labor and the postdelivery period in the remifentanil group, as compared with the meperidine group. The study was terminated after 17 patients were enrolled, however, because of the high incidence of low Apgar scores in babies of the mothers treated with meperidine.
In a study comparing PCIA remifentanil and intramuscular meperidine (open pilot study) [11] , remifentanil provided better pain relief but the maternal respiratory depressant effect was more prominent than with intramuscular meperidine. In another study, Blair et al. [39] Blair et al. [43] compared the analgesic efficacy of PCIA remifentanil (bolus 40 mg and lockout interval 2 min) with PCIA meperidine (bolus 15 mg and lockout 10 min) in 49 healthy parturient women. Entonox (50 : 50 oxygennitrous oxide mixture) was used freely by 75% of the women during labor. Pain relief and maternal oxygen saturation were similar in the two groups [6.4 versus 6.9 (out of a maximum of 10 on a visual-analogue scale)], whereas satisfaction was higher in the remifentanil group. Neonatal neurologic and adaptive capacity scores at 30 min were higher in the remifentanil group than in the meperidine group.
Volikas et al. [44] utilized PCIA remifentanil without a baseline infusion in 50 parturients. The results were compared with baseline results (no control group was used). Remifentanil administered at a bolus dose of 0.5 mg/kg and lockout interval of 2 min without baseline infusion provided adequate pain relief in 43 out of 50 women, with acceptable maternal side effects [nausea, itching and drowsiness (but alert to voice stimulation)] and minimal neonatal effects (fetal heart rate changes that did not require intervention).
Volmanen et al. [45] described the successful use of PCIA remifentanil with a bolus dose of 0.4 mg/kg and a lockout time of 1 min and without baseline infusion, as compared with intermittent use of 50% nitrous oxide in 20 parturient women. Remifentanil provided better labor analgesia, a decrease in pain score (reduction in analogue pain score:
1.5 points in the remifentanil group versus 0.5 points in the nitrous oxide group), but with more sedative effects and desaturations. Most of the women preferred remifentanil administration.
Evron et al. [46] compared the analgesic efficacy and adverse effects of remifentanil and meperidine in a double-blind randomized controlled trial in 88 parturients. PCIA with remifentanil was administered at increasing bolus doses form 0.27 to 0.93 mg/kg; in the meperidine group, each woman received an intravenous infusion at a dose of 75-200 mg. Remifentanil provided more effective and reliable analgesia with greater satisfaction scores compared with meperidine. Sedative effects and hemoglobin desaturations were recorded less frequently in the remifentanil group. There were fewer nonreassuring fetal heart rate patterns with remifentanil administration than with meperidine. Neonatal outcomes were similar in the two groups. The preferable mode of remifentanil administration suggested by this study was PCIA in an intermittent incremental regimen.
In summary, remifentanil has been administered as intravenous analgesia for labor using a variety of methods, including baseline infusion, PCIA boluses (with or without baseline infusion), and target-controlled infusions. The intermittent escalating PCIA bolus dose regimen has apparent advantages because it accounts for interindividual variability in response to pain.
The increase in intensity of painful contractions depends on the stage of labor, and it may be difficult to anticipate forthcoming uterine contractions. Although it is logical to estimate that the time from initiation of the bolus to the effect would approximate 2 min and the maximum effect would occur toward the end of the contraction, the halflife time for the effect of remifentanil is longer than the plasma half-life. Glass et al. [25] showed that the analgesic effect of remifentanil was reduced to half within 6 min of its administration in healthy volunteers. The delay in disappearance of the analgesic effect of remifentanil may be responsible for the pain relief during subsequent contractions. Such prolongation of clinical effect was also suggested by Babenco et al. [47] , who found that the halflife time for the ventilatory depressant effects of remifentanil was not as brief as its plasma half-life. The side effects of remifentanil mimic those of the other opioids, including chest wall rigidity, when used as an adjunct in general anesthesia [48] .
Conclusion
We conclude that remifentanil may be a suitable systemic analgesic for labor pain, when regional analgesia is unavailable or contraindicated. Its analgesic efficacy and safety in labor are now well established. Its use remains experimental, however, and careful fetal/ maternal monitoring is therefore mandatory with this drug. Larger, randomized controlled trials are necessary to investigate further maternal and fetal side effects and to legitimize its routine use in obstetric analgesia.
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